Barclays Upgrades GlaxoSmithKline (GSK) to Overweight
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $50.72 -0.7%
Rating Summary:
7 Buy, 15 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 48
Rating Summary:
7 Buy, 15 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 48
Join SI Premium – FREE
Barclays upgraded GlaxoSmithKline (NYSE: GSK) from Equalweight to Overweight.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $44.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Upgrades Valeo SA (FR:FP) (VLEEY) to Buy
- Kepler Cheuvreux Upgrades Shaftesbury Capital PLC (SHC:LN) to Hold
- Cantor Fitzgerald Upgrades Omeros Corp. (OMER) to Overweight, 'We May Have Underestimated Yartemlea'
Create E-mail Alert Related Categories
UpgradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
